DIKUL - logo
E-viri
Celotno besedilo
Recenzirano Odprti dostop
  • In chronic lymphocytic leuk...
    Rigolin, Gian Matteo; Saccenti, Elena; Melandri, Aurora; Cavallari, Maurizio; Urso, Antonio; Rotondo, Francesco; Betulla, Anita; Tognolo, Lucia; Bardi, Maria Antonella; Rossini, Marika; Tammiso, Elisa; Bassi, Christian; Cavazzini, Francesco; Negrini, Massimo; Cuneo, Antonio

    British journal of haematology, March 2021, Letnik: 192, Številka: 6
    Journal Article

    Summary In a series of 349 patients with chronic lymphocytic leukaemia (CLL), we found lower levels of signalling lymphocytic activation molecule family member 1 (SLAMF1) expression in cases with highly complex karyotypes, as defined by the presence of five or more chromosomal abnormalities (CK5; P < 0·001) and with major chromosomal structural abnormalities (P < 0·001). SLAMF1 downregulation was significantly associated with advanced Binet Stage (P = 0·001), CD38 positivity (P < 0·001), high β2‐microglobulin levels (P < 0·001), immunoglobulin heavy chain variable region gene (IGHV) unmutated status (P < 0·001), 11q deletion (P < 0·001), tumour protein p53 (TP53) disruption (P = 0·011) and higher risk CLL International Prognostic Index categories (P < 0·001). Multivariate analysis showed that downregulated SLAMF1 levels had independent negative prognostic impact on time‐to‐first treatment (P < 0·001) and overall survival (P < 0·001).